SEC Form 4 · accession 0001209191-18-015010
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eilon D. Kirson
Officer — Chief Science Officer
Period of report
Feb 27, 2018
Accepted (ET)
Mar 1, 2018 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF1 | $21.15 | Feb 27, 2018 | A | 152,068 | A | — | Feb 27, 2028 | Ordinary Shares | 152,068 | 152,068 | D |
| Restricted Stock UnitF2,F3 | — | Feb 27, 2018 | A | 20,833 | A | — | — | Ordinary Shares | 20,833 | 20,833 | D |
Explanation of responses
- F1Options to buy 152,068 ordinary shares will vest and become exercisable in equal installments on each of February 27, 2019, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates.
- F2Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.
- F3One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates.